隆基股份(601012.SH):2018年度配股募投項目結項 結餘募集資金用於新建項目及永久補充流動資金
格隆匯12月24日丨隆基股份(601012.SH)公佈,鑑於寧夏樂葉年產5GW高效單晶電池項目和滁州樂葉年產5GW高效單晶組件項目均已建設完畢,並均已達到預定可使用狀態,為最大程度地發揮募集資金使用效益,提升公司經營業績,提高對股東的回報,在扣除尚未支付的項目建設尾款及質保金等後續支出後,公司擬將寧夏樂葉年產5GW高效單晶電池項目結餘募集資金12億元用於新建項目投資建設,剩餘的1698.82萬元永久性補充流動資金;將滁州樂葉年產5GW高效單晶組件項目結餘募集資金1.77億元用於永久性補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.